source
- Telix to acquire Germany's ITM for $1.65 billion, aiming to dominate radiopharmaceutical marketTelix, an Australian radiopharmaceutical diagnostics company, announced it will purchase German developer ITM in a cash transaction valued at $1.65 billion upfront. The agreement gives Telix the o…
- New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budgetThe FDA has approved daraxonrasib, a therapy from Revolution Medicines that targets the KRAS mutation in pancreatic cancer. The drug is intended for patients who have already received treatment and…